➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Express Scripts
Mallinckrodt
AstraZeneca
Harvard Business School

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,750,747

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,750,747 protect, and when does it expire?

Patent 9,750,747 protects APTIOM and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 9,750,747
Title:Treatments involving eslicarbazepine acetate or eslicarbazepine
Abstract: The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.
Inventor(s): Soares Da Silva; Patricio Manuel Vieira Araujo (Sao Mamede do Coronado, PT)
Assignee: BAIL-PORTELA & CA, S.A. (Sao Mamede do Coronado, PT)
Application Number:14/240,847
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,750,747
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 9,750,747

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,750,747

PCT Information
PCT FiledAugust 24, 2012PCT Application Number:PCT/PT2012/000031
PCT Publication Date:March 07, 2013PCT Publication Number: WO2013/032351

International Family Members for US Patent 9,750,747

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2847235   Start Trial
European Patent Office 2747770   Start Trial
Russian Federation 2014111478   Start Trial
Russian Federation 2639120   Start Trial
World Intellectual Property Organization (WIPO) 2013032351   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Moodys
McKesson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.